The First Affiliated Hospital with Nanjing Medical University
Phase
Phase EARLY_PHASE1
Started
2025-12-10
Last updated
2025-12-19
Condition(s) studied
Multiple Myeloma
Investigational drug(s) / intervention(s)
LVIVO-TaVec200 product
LVIVO-TaVec200 product: Prior to infusion of the LVIVO-TaVec200 product, subjects will receive bridging therapy if needed.
Study summary
This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec200 in the treatment of relapsed/refractory multiple myeloma.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Subjects voluntarily participate in clinical studies; Fully informed of this study and signed informed consent; Informed consent form must be obtained prior to initiation of any study-related tests or procedures that are not part of the standard treatment for the subject's disease; Good compliance and cooperation with follow-up.
2. Age ≥ 18 years.
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
4. Has measurable lesions
5. Relapsed and/or refractory multiple myeloma
6. Life expectancy≥ 3 months
7. Clinical laboratory values meet screening visit criteria
8. Adequate organ function.
Exclusion Criteria:
1. Prior antitumor therapy with insufficient washout period ;
2. Prior treatment targeting GPRC5D;
3. Patients who are positive for hepatitis B surface antigen (HBsAg), hepatitis B virus deoxyribonucleic acid (HBV DNA), hepatitis C antibody (HCV-Ab), hepatitis C virus ribonucleic acid (HCV RNA), and human immunodeficiency virus antibody (HIV-Ab).
4. Known life-threatening allergic reaction, hypersensitivity reaction, or intolerance to study drug excipients and related excipients, including but not limited to DMSO; or those with a history of severe allergic reactions in the past (such as hypersensitivity reactions, or those with severe immune-related reactions such as the need for glucocorticoids to prevent anaphylaxis as assessed by the investigator).
5. Any condition deemed by the investigator as rendering the subject unsuitable for participation in this study.
Primary outcome measure(s)
Incidence, severity and type of TEAEs (Treatment-emergent Adverse Events) — Through study completion, an average of 2 years after LVIVO-TaVec200 infusion (Day 1) An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
Pharmacokinetics in peripheral blood — Through study completion, an average of 2 years after LVIVO-TaVec200 infusion (Day 1) CAR positive T cells and CAR transgene percentage of in peripheral blood after LVIVO-TaVec200 infusion
Pharmacokinetics in bone marrow — Through study completion, an average of 2 years after LVIVO-TaVec200 infusion (Day 1) CAR positive T cells and CAR transgene percentage of in bone marrow after LVIVO-TaVec200 infusion
The recommended Phase II dose (RP2D) for this cell — 30 days after LVIVO-TaVec200 infusion RP2D established through BF-BOIN design and the DLTs occurring following LVIVO-TaVec200 infusion
Trial sites (5)
Facility
City
Region
Status
Henan Cancer Hospital
Zhengzhou
Henan
Not Yet Recruiting
The First Affiliated Hospital with Nanjing Medical University
Nanjing
Jiangsu
Recruiting
The Affiliated Hospital of XUZHOU Medical University
Xuzhou
Jiangsu
Not Yet Recruiting
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai
Shanghai Municipality
Not Yet Recruiting
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi’an
Shanxi
Not Yet Recruiting
More The First Affiliated Hospital with Nanjing Medical University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.